Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Onconova Therapeutics, Inc. (ONTX)

0.851   -0.014 (-1.66%) 01-27 15:59
Open: 0.86 Pre. Close: 0.8654
High: 0.8699 Low: 0.8275
Volume: 74,239 Market Cap: 18(M)

Technical analysis

as of: 2023-01-27 4:46:51 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.07     One year: 1.25
Support: Support1: 0.73    Support2: 0.62
Resistance: Resistance1: 0.92    Resistance2: 1.07
Pivot: 0.82
Moving Average: MA(5): 0.85     MA(20): 0.78
MA(100): 0.82     MA(250): 1.18
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 70.2     %D(3): 70.6
RSI: RSI(14): 58.4
52-week: High: 2.03  Low: 0.62
Average Vol(K): 3-Month: 84 (K)  10-Days: 69 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ONTX ] has closed below upper band by 38.0%. Bollinger Bands are 0.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.87 - 0.88 0.88 - 0.88
Low: 0.82 - 0.82 0.82 - 0.83
Close: 0.84 - 0.85 0.85 - 0.86

Company Description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Headline News

Thu, 26 Jan 2023
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series - Yahoo Finance

Mon, 23 Jan 2023
Mental health resources across Canada - CTV News

Sun, 22 Jan 2023
Cadrenal Therapeutics Stock (NASDAQ:CVKD), Quotes and News ... - Benzinga

Wed, 07 Dec 2022
Onconova Therapeutics to Present at the Upcoming MedInvest ... - GlobeNewswire

Mon, 28 Nov 2022
Onconova Therapeutics to Present at the Upcoming RHK Capital ... - GlobeNewswire

Mon, 07 Nov 2022
Onconova Therapeutics to Provide Corporate Update and ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 21 (M)
% Held by Insiders 2.081e+007 (%)
% Held by Institutions 0.4 (%)
Shares Short 16 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.764e+007
EPS Est Next Qtl -0.76
EPS Est This Year -2.86
EPS Est Next Year -2.1
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -7
Return on Assets (ttm) 812.3
Return on Equity (ttm) -21.3
Qtrly Rev. Growth 226000
Gross Profit (p.s.) 0
Sales Per Share -27.25
EBITDA (p.s.) 147712
Qtrly Earnings Growth -0.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -17 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 0.81

Stock Dividends

Dividend 0
Forward Dividend 7290
Dividend Yield 0%
Dividend Pay Date 2018-09-25
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.